WHO ICTRP trial
Study on the pathological mechanism of macular edema caused by retinal vein…
ChiCTR2300069732 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2300069732 |
|---|---|
| Public title | Study on the pathological mechanism of macular edema caused by retinal vein occlusion and related factors affecting treatment prognosis by MLC combined with aqueous humor cytokine detection |
| Scientific title | Study on the pathological mechanism of macular edema caused by retinal vein occlusion and related factors affecting treatment prognosis by MLC combined with aqueous humor cytokine detection |
| Primary sponsor | Qingdao Eye Hospital of Shandong First Medical University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 4 |
| Countries | China |
| Conditions | Retinal vein occlusion |
| Interventions | Anti-VEGF treatment group:Intravitreal injection of Aflibercept;Ozurdex treatment group:Intravitreal injection of Ozurdex |
| Registration date | Mar 24, 2023 |
| Target size | Anti-VEGF treatment group:30;Ozurdex treatment group:30 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: